Natural History Study of Batten Disease

Emily de los Reyes10 enrolled

Overview

This is a multicenter, international, study to assess the natural history data from people with Batten disease by collecting both retrospective and prospective information about the motor, behavioral and functional capabilities of patients. The study initially has 2 cohorts. Cohort 1 (n ≈ 75) includes subjects with CLN6 Batten disease. Cohort 2 (n ≈ 120) includes subjects with juvenile CLN3 Batten disease. Additional cohorts for other Batten disease subtypes may be added in the future.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Batten Disease Neuronal Ceroid Lipofuscinosis CLN6 Neuronal Ceroid Lipofuscinosis CLN3

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Subject has or had a diagnosis of CLN6 or CLN3 Batten disease that has been confirmed by genotyping (documented presence of a variant on both gene alleles). Confirmation of genotyping will be performed prior to enrollment. * Subject (or legally authorized representative) has provided written informed consent (or assent) and authorization for use and disclosure of personal health information or research related health information * Subjects may enroll starting from birth Exclusion Criteria: * Subject has or had experienced another illness that is known to cause cognitive decline (eg, trauma, meningitis, hemorrhage) * Subject received or receives an investigational gene therapy

Locations (1)

University of Rochester Medical Center

Rochester, New York, United States

Outcomes

Primary Outcomes

Assess the change over time in rating as determined using the Unified Batten Disease Rating Scale (UBDRS).

The UBDRS is a clinical ratings instrument used specifically to assess motor, seizure, behavioral and functional capabilities.

Time frame: 10 years

Assess the change over time in rating as determined using the Hamburg Scale.

The Hamburg scale is an established tool to capture the rate of decline or regression.

Time frame: 10 years

Assess the change over time in cognitive function using Mullen Scales of Early Learning (for children up to 60 months old).

Time frame: 10 years

Assess the change over time in cognitive function using WPPSI-IV (for children up to 7 years 7 months old).

Time frame: 10 years

Assess the change over time in cognitive function using WISC-V (for patients older than 6 years old).

Time frame: 10 years

Characterize the age of onset of disease, including the timing of both the loss of capacities and the emergence of disease-related signs and symptoms

Time frame: 10 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.